Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.61 |
| ▸ | CCR2 | P41597 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918426 | 0.81 | KDM4E (0.66) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL6356421 | 0.78 | SIGMAR1 (0.62) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL11465989 | 0.77 | SIGMAR1 (0.62) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL19466028 | 0.77 | ACHE (0.58) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL4465185 | 0.77 | MEN1 (0.55) | ROCK2ROCK1CCR2ACHEHRH3 | |
| SCHEMBL924357 | 0.76 | ACHE (0.68) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL5409256 | 0.76 | ROCK2 (0.83) | ROCK2ROCK1CCR2KDM4EKMT2A | |
| SCHEMBL224917 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL7288248 | 0.75 | ACHE (0.68) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL15919764 | 0.75 | SIGMAR1 (0.62) | ROCK2ROCK1CCR2ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-03 | — | — | US | disclosed |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-02 | — | — | US | disclosed |
| EP-3442960-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017178510-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | OPRD1, TRPV1, OPRL1 | ROCK2 3123/4885ROCK1 4414/4885CCR2 523/4885 |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, TRPV1, OPRL1 | ROCK2 3123/4885ROCK1 4414/4885CCR2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.